UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Cancer science, 2010-03, Vol.101 (3), p.826-830

2010

Volltextzugriff (PDF)

Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation

Journal of clinical oncology, 2001-01, Vol.19 (1), p.37-43

2001

Volltextzugriff (PDF)

Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer

Journal of clinical oncology, 2004-05, Vol.22 (9), p.1614-1620

2004

Volltextzugriff (PDF)

HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer

Journal of clinical oncology, 2003-02, Vol.21 (3), p.458-462

2003

Volltextzugriff (PDF)

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

BMJ, 2005-01, Vol.330 (7485), p.217-220

International edition, 2005

Volltextzugriff (PDF)

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98)

Cancer, 2014-03, Vol.120 (6), p.885-893

2014

Volltextzugriff (PDF)

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy

Breast (Edinburgh), 2015-06, Vol.24 (3), p.294-297

2015

Volltextzugriff (PDF)

Single Institution trial of anthracycline‐ and taxane‐based chemotherapy for operable breast cancer: The ASTER study

The breast journal, 2019-03, Vol.25 (2), p.237-242

2019

Volltextzugriff (PDF)

Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

The New England journal of medicine, 1995-04, Vol.332 (14), p.901-906

1995

Volltextzugriff (PDF)

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

Journal of clinical oncology, 1998-01, Vol.16 (1), p.93-100

1998

Volltextzugriff (PDF)

Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1110-1110

2014

Volltextzugriff (PDF)

Maspin influences response to doxorubicin by changing the tumor microenvironment organization

International journal of cancer, 2014-06, Vol.134 (12), p.2789-2797

2014

Volltextzugriff (PDF)

Abstract LB-320: Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.LB-320-LB-320

2013

Volltextzugriff (PDF)

Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e11509-e11509

2014

Volltextzugriff (PDF)

Axillary Lymph Node Dissection Versus No Dissection in Patients With T1NO Breast Cancer: A Randomized Clinical Trial (INT09/98)

Cancer, 2014, Vol.120 (6), p.885-893

2014

Volltextzugriff (PDF)

Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.537-537

2013

Volltextzugriff (PDF)

Local Recurrences Following Mastectomy: Support for the Concept of Tumor Dormancy

JNCI : Journal of the National Cancer Institute, 1994-01, Vol.86 (1), p.45-48

1994

Volltextzugriff (PDF)

Adjuvant and neoadjuvant treatment of breast cancer

Seminars in oncology, 2001-02, Vol.28 (1), p.13-29

2001

Volltextzugriff (PDF)

Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study

Clinical breast cancer, 2006-10, Vol.7 (4), p.321-325

2006

Volltextzugriff (PDF)

Adjuvant and neoadjuvant treatment of breast cancer

Seminars in oncology, 2001-02, Vol.28 (1), p.13-29, Article asonc0280013

2001

Volltextzugriff (PDF)

Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005

Breast cancer research and treatment, 2006-06, Vol.97 (3), p.341-343

2006

Volltextzugriff (PDF)

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'

Breast cancer research and treatment, 1999-02, Vol.53 (3), p.209-215

1999

Volltextzugriff (PDF)

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes

Journal of clinical oncology, 1991-07, Vol.9 (7), p.1124-1130

1991

Volltextzugriff (PDF)

Vinorelbine : an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

Breast cancer research and treatment, 1996-01, Vol.39 (3), p.285-291

1996

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(119)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Physical Sciences
(59)
Crystallography
(55)
Chemistry
(46)
Chemistry, Multidisciplinary
(46)
Crystal Structure
(25)
Physics
(23)
Humans
(22)
Condensed Matter: Structure, Mechanical And Thermal Properties
(21)
Exact Sciences And Technology
(21)
Female
(21)
Structure Of Solids And Liquids; Crystallography
(21)
Life Sciences & Biomedicine
(19)
Powder Diffraction
(17)
Breast Neoplasms - Drug Therapy
(16)
Diffraction
(16)
Oncology
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Adult
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation

Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer

HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98)

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy

Single Institution trial of anthracycline‐ and taxane‐based chemotherapy for operable breast cancer: The ASTER study

Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer

Maspin influences response to doxorubicin by changing the tumor microenvironment organization

Abstract LB-320: Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer

Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience

Axillary Lymph Node Dissection Versus No Dissection in Patients With T1NO Breast Cancer: A Randomized Clinical Trial (INT09/98)

Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO)

Local Recurrences Following Mastectomy: Support for the Concept of Tumor Dormancy

Adjuvant and neoadjuvant treatment of breast cancer

Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study

Adjuvant and neoadjuvant treatment of breast cancer

Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes

Vinorelbine : an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

Suchergebnisse filtern